🇺🇸 FDA
Patent

US 11655286

Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11655286 (Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/40, A61K45/06